-transparent.png){kind=logo}
10 patients with advanced non-Hodgkin's lymphoma of low malignancy were treated with partially purified HulFN-beta. They received daily i.v. infusions of 4.5 X 10(6) IU for 4 weeks, followed by 9 X 10(6) IU daily for 2 weeks. Patients with stable disease during this period received consolidation therapy with 4.5 X 10(6) IU three times per week for a maximum of 20 weeks. Six out of 10 patients had progressive disease after the initial 6 week treatment and 4 had stable disease. Two of the latter developed progressive disease during consolidation therapy, one had a complete remission of minimal bone marrow involvement, and one was in partial remission with a loss of bone marrow infiltration but unchanged lymph node enlargement.
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
February 1987,
British journal of cancer,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
October 1995,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
June 1991,
Anales de medicina interna (Madrid, Spain : 1984),
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
May 1985,
The New England journal of medicine,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
January 1990,
Haematologica,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
June 1988,
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
March 1994,
Cancer,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
September 1994,
Cancer,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
January 1994,
Wiener klinische Wochenschrift,
W Siegert, and
H Theml, and
U Fink, and
B Emmerich, and
P Kaudewitz, and
D Huhn, and
L Böning, and
J Abb, and
K E Joester, and
R Bartl, and
G Riethmüller, and
W Wilmanns
June 2001,
Anti-cancer drugs,
